Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
2.690
-0.100 (-3.58%)
Nov 21, 2024, 4:00 PM EST - Market closed
Inozyme Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 21.43 | 20.8 | 20.83 | 19.63 | 11.25 | 5.04 | |
| Research & Development | 78.24 | 54.85 | 47.85 | 37.02 | 45.79 | 15.77 | |
| Operating Expenses | 99.67 | 75.65 | 68.68 | 56.65 | 57.04 | 20.81 | |
| Operating Income | -99.67 | -75.65 | -68.68 | -56.65 | -57.04 | -20.81 | |
| Interest Expense | -5.42 | -3.33 | -0.26 | - | - | - | |
| Interest & Investment Income | 8.71 | 7.84 | 2.2 | 0.21 | 0.37 | 1.11 | |
| Currency Exchange Gain (Loss) | - | - | - | -0.03 | 0.25 | -0.02 | |
| Other Non Operating Income (Expenses) | -0.12 | -0.03 | -0.32 | -0.16 | - | - | |
| Pretax Income | -96.49 | -71.17 | -67.06 | -56.62 | -56.42 | -19.72 | |
| Net Income | -96.49 | -71.17 | -67.06 | -56.62 | -56.42 | -19.72 | |
| Net Income to Common | -96.49 | -71.17 | -67.06 | -56.62 | -56.42 | -19.72 | |
| Shares Outstanding (Basic) | 62 | 52 | 38 | 24 | 11 | 1 | |
| Shares Outstanding (Diluted) | 62 | 52 | 38 | 24 | 11 | 1 | |
| Shares Change (YoY) | 31.49% | 37.27% | 60.30% | 113.46% | 832.81% | 12.60% | |
| EPS (Basic) | -1.55 | -1.37 | -1.78 | -2.40 | -5.11 | -16.67 | |
| EPS (Diluted) | -1.55 | -1.37 | -1.78 | -2.40 | -5.11 | -16.67 | |
| Free Cash Flow | -91.36 | -70.97 | -58.17 | -48.55 | -36.54 | -18.95 | |
| Free Cash Flow Per Share | -1.47 | -1.37 | -1.54 | -2.06 | -3.31 | -16.02 | |
| EBITDA | -98.89 | -74.81 | -67.93 | -55.97 | -56.82 | -20.72 | |
| D&A For EBITDA | 0.77 | 0.83 | 0.74 | 0.67 | 0.22 | 0.08 | |
| EBIT | -99.67 | -75.65 | -68.68 | -56.65 | -57.04 | -20.81 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.